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ARTICLE
Genetics and Genomics
Candidate biomarkers of PARP inhibitor sensitivity in ovarian
cancer beyond the BRCA genes
Darren R. Hodgson1, Brian A. Dougherty2, Zhongwu Lai2, Anitra Fielding1, Lynda Grinsted1, Stuart Spencer1, Mark J. O’Connor1,
Tony W. Ho3, Jane D. Robertson1,9, Jerry S. Lanchbury4, Kirsten M. Timms4, Alexander Gutin4, Maria Orr1, Helen Jones1, Blake Gilks5,
Chris Womack6, Charlie Gourley7, Jonathan Ledermann8 and J. Carl Barrett2
BACKGROUND: Olaparib (Lynparza™) is a PARP inhibitor approved for advanced BRCA-mutated (BRCAm) ovarian cancer. PARP
inhibitors may benefit patients whose tumours are dysfunctional in DNA repair mechanisms unrelated to BRCA1/2. We report
exploratory analyses, including the long-term outcome of candidate biomarkers of sensitivity to olaparib in BRCA wild-type
(BRCAwt) tumours.
METHODS: Tumour samples from an olaparib maintenance monotherapy trial (Study 19, D0810C00019; NCT00753545) were
analysed. Analyses included classification of mutations in genes involved in homologous recombination repair (HRR), BRCA1
promoter methylation status, measurement of BRCA1 protein and Myriad HRD score.
RESULTS: Patients with BRCAm tumours gained most benefit from olaparib; a similar treatment benefit was also observed in 21/95
patients whose tumours were BRCAwt but had loss-of-function HRR mutations compared to patients with no detectable HRR
mutations (58/95). A higher median Myriad MyChoice® HRD score was observed in BRCAm and BRCAwt tumours with BRCA1
methylation. Patients without BRCAm tumours derived benefit from olaparib treatment vs placebo although to a lesser extent than
BRCAm patients.
CONCLUSIONS: Ovarian cancer patients with tumours harbouring loss-of-function mutations in HRR genes other than BRCA1/2may
constitute a small, molecularly identifiable and clinically relevant population who derive treatment benefit from olaparib similar to
patients with BRCAm.
British Journal of Cancer https://doi.org/10.1038/s41416-018-0274-8
INTRODUCTION
Poly(ADP-ribose) polymerase (PARP) plays a vital role in the repair
of single-strand DNA breaks through the base excision repair
pathway. PARP inhibitors are thought to become trapped at the
sites of single-strand DNA breaks leading to double-strand DNA
breaks when DNA replication is attempted.1 The double-strand
DNA breaks would normally be repaired by the process of
homologous recombination repair (HRR), which is a complex
process including many proteins, notably BRCA1 and BRCA2.2
Tumours with an HRR deficiency, such as those found in BRCA-
mutated cancers, cannot accurately repair DNA damage when
PARP protein function is also disrupted and both the base excision
and HRR DNA repair pathways are rendered inoperative. In these
tumours, DNA repair by low fidelity repair mechanisms such as
non-homologous end joining can cause the accumulation of
genomic instability, ultimately resulting in cell death; a concept
referred to as synthetic lethality.3 Additionally, preclinical data
suggest that PARP inhibitors may also benefit patients whose
tumours are sensitive to platinum-based chemotherapy and who
have an HRR deficiency caused by mutations other than those in
the BRCA1/2 genes.4,5 Hence, the clinical and molecular profiles of
high-grade serous ovarian cancer (SOC) appeared well matched to
PARP inhibitor biology, as this cancer is noted for genome
instability thought to be driven by HRR deficiency, repeated and
prolonged platinum sensitivity and a high frequency of deficiency
in BRCA and other candidate HRR proteins.6
Maintenance treatment with the PARP inhibitor olaparib
(Lynparza™) in an AstraZeneca-sponsored, randomised, phase II
trial of 265 patients with platinum-sensitive relapsed high-grade
SOC (Study 19, D0810C00019; NCT00753545) led to a significant
increase in progression-free survival (PFS) vs placebo, which was
greatest in the subgroup of 136 patients with BRCA1/2-mutated
tumours (hazard ratio 0.18; 95% confidence interval [CI] 0.10–0.31;
P < 0.001).7 This subgroup included patients with inherited and
somatic (tumour only) mutations.7 Recent analyses strongly
suggest that somatic loss-of-function mutations in BRCA1 and
BRCA2 are an early event in the development of high-grade SOC
and that tumours with somatic BRCA mutations phenocopy
tumours in patients with inherited germline BRCA mutations in
terms of genetic epidemiology, natural history and response to
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platinum chemotherapy, and response to olaparib and other PARP
inhibitors.8–13
Of interest, in Study 19 a significant PFS benefit for olaparib vs
placebo was also observed in the subgroup of 118 patients with
wild-type BRCA tumours, although the treatment benefit was less
(PFS hazard ratio 0.54; 95% CI 0.34–0.85; P < 0.01) than in those
patients with BRCA-mutated tumours.7 A similar trend of broad
activity in ovarian cancer with a stronger effect in tumours with
BRCA mutations has been noted for other PARP inhibitors.11–13
Hence, there is considerable interest in understanding the
molecular basis of sensitivity to PARP inhibitors in patients whose
tumours do not have mutations in the BRCA genes and in tumour
tests that may aid in the identification of patients who will benefit
most from treatment. In particular, an important question to
address is whether in BRCA wild-type tumours, mutations in other
HRR genes account for the benefit observed. To further
characterise genetic changes in SOC tumours, we conducted
exploratory candidate biomarker analyses on BRCA wild-type
tumour samples from Study 19 and investigated the possible
relationship of HRR deficiencies and clinical benefit.
MATERIALS AND METHODS
Study design and population
Study 19 was a phase II, randomised, double-blind, multicentre
trial, undertaken at 82 sites in 16 countries. The study design,
patient population and statistical analyses have previously been
published in detail.7,14 In brief, eligible patients were aged 18
years or older and had relapsed SOC (Grade 2 or 3) that was
platinum sensitive. Patients entering the study were required to
have received two or more previous courses of platinum-based
chemotherapy and to have demonstrated an objective response
(complete or partial) according to Response Evaluation Criteria in
Solid Tumors (RECIST) or Gynecologic Cancer InterGroup criteria.
Patients were randomised 1:1 to receive either olaparib 400mg
twice daily (b.i.d.) capsules or matching placebo. Study treatment
was continued until progression in the absence of unacceptable
toxicity. The primary endpoint was PFS, as determined by RECIST
v1.0, and overall survival (OS) was a secondary endpoint.
Exploratory analyses
To identify patients that benefit from olaparib that do not have
BRCA mutations, exploratory biomarker analyses were conducted
on tumour samples from Study 19 including BRCA1 promoter
methylation, BRCA1 protein expression, HRR gene mutation, and
Myriad homologous recombination deficiency (HRD) testing
(which includes a tumour test for BRCA mutations).
BRCA-mutated and BRCA wild-type subgroups in Study 19. Analysis
of the BRCA mutation status of patients was prespecified in the
Study 19 statistical analysis plan. Molecular analyses to define the
BRCA status of patients in Study 19 were completed retro-
spectively and were blinded to clinical outcomes.7 In brief, the
BRCA-mutated population comprised patients with a mutation in
their tumour and/or blood sample. Germline BRCA mutation status
was either reported on case report forms after local testing or was
established retrospectively using the Integrated BRACAnalysis®
assay (Myriad Genetics Laboratories, Salt Lake City, UT, USA), with
DNA extracted from blood samples obtained prior to randomisa-
tion.15
The analyses presented here are based on BRCA mutation status
subgroups defined retrospectively, which were blind to clinical
outcomes but were not prespecified in the Study 19 statistical
analysis plan.
Tumour samples. The provision of an archival tumour sample
(blocks or sections) was mandatory for participation in Study 19.
Samples received as blocks were made into tumour microarrays
with two 0.6 mm cores from each tumour at the University of
British Columbia.
HRR mutation status. Tumour mutation status in BRCA1, BRCA2
and other key HRR-related genes was established using the same
DNA sequencing analysis performed to determine tumour BRCA
mutation status as previously described.7 In brief, DNA was
extracted from formalin-fixed, paraffin-embedded (FFPE) archival
tumour samples using a cancer gene panel enrichment procedure
and deep resequencing performed with Illumina technology.
Specifically, analysis was not performed with the commercially
available Foundation Focus diagnostic test but with the Founda-
tion Medicine T5 panel (entire coding sequence of 287 cancer-
related genes plus select introns from 27 genes and other genetic
alterations, deletions and functional rearrangements) at Founda-
tion Medicine (Cambridge, MA, USA).16 Tumour analysis was
performed on coded tumour samples and results were returned
blind to the original Study 19 data set. The classification of variants
was based on the American College of Medical Genetics
recommendations. Patients with no known BRCA mutation and
patients with a BRCA mutation classed as a variant of unknown
significance (VUS) were included in the BRCA wild-type group as
previously described.7
Patients in the BRCA wild-type group were further subdivided
into three groups: BRCA wild-type HRR-mutated, patients whose
tumours had a loss-of-function mutation in a high-confidence HRR
gene; HRR status unknown, patients with a potential loss-of-
function mutation in any gene associated with DNA repair; and
BRCA and HRR wild type, patients with no potential loss-of-
function mutations in any gene involved in DNA repair. The HRR
genes interrogated are listed in Supplementary Table 1.
Myriad MyChoice® HRR deficiency test and BRCA1 promoter
methylation analysis of tumour samples
Tumour samples were analysed as described by Timms et al.
(2014).17 Next-generation sequencing-based assays were used to
generate genome-wide single-nucleotide polymorphism profiles,
BRCA1/2 mutation screening and BRCA1 promoter methylation
data. These analyses separately reported tumour BRCA mutation
(tBRCAm) status, tumour BRCA1 methylation status and tumour
HRD score. An HRD score ≥42 was considered positive. The
reported results are based on a research assay performed at
Myriad Genetics and not upon the commercially available test.18
Immunohistochemistry for BRCA1
FFPE sections of 4 µm thickness were cut and mounted on
SuperFrost Plus™ electrostatically charged glass slides and dried
overnight at 37 °C in an incubator. Sections were dewaxed in
xylene, passed through a graded alcohol series and optimal
antigen retrieval obtained using Dako pH 9 antigen retrieval buffer
(Dako, Copenhagen, Denmark), heated in the RHS Microwave
Histo-processor (Milestone, Italy) to 110 °C with full pressure
sustained for 2 min. The pressure vessel was then cooled under
running tap water, the lid removed, and the slides washed.
Immunohistochemical staining was performed at room
temperature on a Lab Vision 720 Autostainer. Sections were
first treated with 3% H2O2 to quench endogenous peroxidase
activity and then blocked with serum-free protein block (Dako).
Following blocking, sections were incubated for 60 min
with anti-BRCA1 (Ab-1) mouse monoclonal antibody (MS110)
at a concentration of 1 µg/ml (OP92; MerckMillipore,
Watford, UK). Visualisation was achieved using Dako REAL™
Envision™, HRP rabbit/mouse (Dako), applied for 30 min,
followed by 10 min incubation in 3,3'-diaminobenzidine. Sec-
tions were lightly counterstained in Carazzi’s haematoxylin,
dehydrated through alcohol grades and mounted under a glass
coverslip with Histomount (RA Lamb; Thermo Fisher Scientific,
MA, USA).
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Staining was negatively controlled by substituting mouse
immunoglobulin fraction, diluted to the same concentration as
that for the primary antibody. Immunostained slides were
evaluated with light microscopy.
Statistical analysis
The primary endpoint for Study 19 was PFS, which was reported
for the full analysis population following a data cutoff (DCO) of 30
June 2010. PFS data were not collected following this DCO.
Collection of time to first subsequent therapy or death (TFST), time
to second subsequent therapy or death (TSST) and OS data
continued, and the interim OS data reported here have a DCO of
May 2016.
Analyses of PFS, TFST, TSST and OS use the same methodology;
namely a Cox proportional hazards model adjusted for treatment,
ethnic descent (Jewish vs non-Jewish), time to progression on
penultimate platinum therapy (6–12 vs >12 months), and
response to platinum therapy before randomisation (complete
response vs partial response). This methodology was used for the
primary analyses of the study.7,14
Where there were fewer than 15 events formal statistical tests
were not performed.
RESULTS
Classification of HRR gene mutation status
Patients with BRCA wild-type and HRR-mutated tumours or BRCA
and HRR wild-type tumours. Archival tumour samples were
available for 253/265 (96%) patients and tumour sequencing
was completed for 209/265 (79%) patients. Forty-four samples
failed due to insufficient tumour cells, DNA quantity, sequencing
library quality or sequence read coverage. As previously
described,7 111/209 patients were classified as having deleterious
or suspected deleterious mutations present in BRCA1 and/or
BRCA2 in their tumour samples and 98 patients had BRCA wild-
type tumours; three further patients were known to have single
exon indels in blood sample DNA but these were below the
detection limit in tumour samples.7 Therefore, 95/209 patients
(45.5%) were classified as having BRCA wild-type tumours. Twenty-
one of these patients (22%) had at least one loss-of-function
mutation in a candidate HRR gene, of whom 12 received olaparib
and 9 received placebo. The specific HRR mutations identified in
the 21 tumour samples were: BRIP1 (n= 5), CDK12 (n= 3), RAD54L
(n= 2), RAD51B (n= 2), RAD54L rearr (n= 1), ATM rearr (n= 1),
FANCA rearr (n= 1), FANCD2 (n= 1), FANCL rearr (n= 1), FANCL (n
= 1), RAD51C (n= 1), RAD52 del (n= 1), XRCC3 rearr (n= 1) (Fig. 1).
For exploratory purposes, we defined a subset of patients as
BRCA-mutated or HRR-mutated as a group containing a loss-of-
function mutation in at least one pathway gene.
Of the remaining 74 patients, 16 were found to have mutations
in genes that are involved more broadly in DNA damage repair
(e.g., MSH2, MUTYH), or in genes where a postulated role in DNA
repair has been the subject of significant controversy (e.g., EMSY);
these patients were classified as HRR unknown. The remaining 58
patients’ tumours did not have a candidate loss-of-function
mutation in a relevant gene. Twenty-five of these patients were
randomised to olaparib and 33 to placebo.
PFS and OS in HRRm and HRRwt patients
PFS was the primary endpoint of Study 19. Patients with a BRCA
result from tumour testing at Foundation Medicine and BRCA wild-
type subsets of Study 19 patients had comparable PFS hazard
ratios to the overall BRCA-mutated (hazard ratio 0.16, 95% CI
0.08–0.3 vs 0.18, 0.10–0.31, respectively) and BRCA wild-type
populations (hazard ratio 0.57, 0.34–0.94 vs 0.54, 0.34–0.85,
respectively) (Fig. 2).7
Data suggest that olaparib is associated with a greater PFS
benefit in HRR-mutated patients without a BRCA mutation (hazard
ratio 0.21, 0.04–0.86) than in patients with no detectable BRCA or
HRR mutation (hazard ratio 0.71, 0.37–1.35) who received olaparib
(Fig. 2). Furthermore, all study endpoints showed a consistent
trend for a larger treatment effect in HRR-mutated patients and a
less positive treatment effect in the patients with no
detectable HRR mutations than in the overall BRCA wild-type
population evaluable for HRR mutation analysis (Supplementary
Table 2).
The PFS hazard ratio for the exploratory subgroup of patients
with a mutation in a BRCA or other HRR gene (n= 157) was 0.20,
95% CI 0.12–0.33. It should be noted that PFS in the ITT population
was the primary endpoint of the study and hence other analyses
are exploratory subgroups of secondary or exploratory endpoints.
Classification of tumour BRCA mutation status, BRCA1 methylation
and HRD score at Myriad
Myriad tumour testing, which comprised BRCA mutation testing,
BRCA1 methylation testing and determining HRD score, was
performed in 219 tumour samples.
Myriad tumour BRCA testing
Myriad tumour BRCA status was reported for 212 patients, of
whom 118 (56%) had a BRCA mutation. In total, BRCA status was
determined for tumours from 235 patients using either the Myriad
and/or Foundation Medicine analyses. Of the 193 patients for
whom tumour BRCA status was available at both laboratories,
tumour samples from 106 patients were classified as mutated and
84 cases were classed as wt/VUS by both laboratories (VUS
samples were predominantly missense variants: impact on gene
function is unknown). The concordance of tumour BRCA testing
between the two laboratories was 98.5% for sequence analysis
(Table 1).
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Fusion g Germline
s Somatic
c Subclonal somatic
Homozygous
Heterozygous
unknown
37.3%
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Known-amplification
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Rearrangement
Known-other
Known-inDel
Unknown
Fig. 1 HRR gene mutations that are mutually exclusive to BRCA1/2. Each column represents one patient from whom tumours were sequenced
(n= 209)
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In the tumour samples from three patients, BRCA mutations
were detected by Myriad testing but not by the Foundation
Medicine test. Myriad testing classified the three BRCA mutations
as a BRCA1 exon 24 deletion, a BRCA1 three-exon duplication and
a BRCA2 32-bp deletion. The efficacy analyses for the Myriad BRCA-
mutated and wild-type tumours were consistent with the
previously published analysis (Fig. 3).7
BRCA1 methylation
Eighteen of the 212 evaluable patients had BRCA1-methylated
tumours, of which the tumours from 16 patients were BRCA wild
type. Four of the 16 BRCA wild-type, BRCA1-methylated patients
were treated with olaparib and 12 with placebo. At the DCO for
PFS, 75% of patients in each arm had disease progression.
Myriad MyChoice homologous recombination deficiency score
Myriad MyChoice HRD scores were determined using an assay that
calculates whole-genome tumour loss of heterozygosity, telomeric
allelic imbalance and large-scale state transition scores.17 The HRD
score is the sum of the three scores which have a bimodal
distribution and a proposed threshold of ≥42.17 Analyses were
performed blind to previous BRCA mutation data.
HRD scores were determined for 199 patients, of whom 139
(70%) were classified as HRD score high (HRD scores ≥42). Of the
139 tumours with high HRD scores, 101 patients (73%) had a BRCA
mutation, 36 (26%) had no BRCAmutation and BRCA analysis failed
in two patients (1%). Of the 60 patients (30%) with low HRD scores
8 patients (13%) had a BRCA mutation, 51 patients (85%) had no
BRCA mutation and 1 (2%) had a failed analysis. Overall, 156
patients would be classified as Myriad HRD positive with a BRCA
mutation in the tumour or a Myriad HRD score ≥42.
Relationships between HRD score, HRR gene mutations and BRCA1
methylation status
BRCA-mutated tumours had the highest median HRD score, HRR-
mutated tumours had an intermediate median HRD score and
tumours without mutations in BRCA or other HRR genes had the
lowest median HRD score (Fig. 4).
HRD scores and efficacy
Olaparib is currently approved for use in patients with platinum-
sensitive relapsed ovarian cancer (PSROC), regardless of BRCA
mutation status, in the US (tablet formulation) and in PSROC
patients with a BRCA mutation in the EU (capsule formulation). We
therefore performed exploratory analyses to examine separately
the impact of HRD scores within patient groups with BRCA
wild-type and BRCA-mutated tumours defined by Myriad tumour
BRCA testing. There were only eight patients with BRCA mutations
and HRD scores <42; this subgroup was not analysed further.
When the prespecified threshold of ≥42 was used to define a BRCA
wild-type HRD high group the PFS hazard ratio (hazard ratio 0.48;
95% CI 0.18–1.27; P= 0.14; n= 36; 20 olaparib, 16 placebo) was
numerically superior to the PFS hazard ratio for the BRCA wild-type
HRD low group (hazard ratio 0.60; 95% CI 0.31–1.17, P= 0.13; n=
51; 25 olaparib, 26 placebo) but was very similar to that for the
overall BRCA wild-type population evaluable for HRD scores
(hazard ratio 0.54; 95% CI 0.32–0.91; P= 0.02; n= 87) (Fig. 3).
Further exploratory analyses did not show a trend for an improved
hazard ratio for PFS with higher Myriad HRD scores in either the
BRCA wild-type or mutated populations when the HRD cut-off was
varied (data not shown). However, the relevant extremes of the
HRD score distribution were only populated by small numbers of
patients such that very few tumours with BRCA mutations had
scores below 30 (n= 1) and conversely few tumours without BRCA
mutations had scores greater than 50 (n= 30). Similar marginal
differences in the hazard ratios observed for PFS between the
BRCA wild-type HRD high group and the BRCA wild-type HRD low
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Fig. 2 PFS and OS by BRCA and HRR status determined at the time of Study 19 and in the exploratory subgroups defined by the Foundation
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classified as tBRCAwt following Foundation Medicine analyses were found to Have BRCAm following germline analysis
Table 1. Myriad tumour BRCA status compared with Foundation
Medicine tumour BRCA status
Myriad tBRCA status Foundation Medicine tBRCA status
BRCAm BRCAwt Missing Total
BRCAm 106 3 9 118
BRCAwt 0 84 10 94
Missing 5 11 37 53
Total 111 98 56 265
BRCAm BRCA mutation, BRCAwt BRCA wild type, tBRCA tumour BRCA
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group were broadly observed for TFST, TSST and OS (Supplemen-
tary Table 3).
The PFS hazard ratio for the exploratory subgroup of patients
with HRD-positive status (n= 156) was 0.24, 95% CI 0.15–0.39. It
should be noted that PFS in the ITT population was the primary
endpoint of the study and hence other analyses are exploratory
subgroups of secondary or exploratory endpoints.
A recent study suggested patients with tumours with HRD
scores <33 are less likely to benefit from platinum
chemotherapy.19 In Study 19 this patient population, BRCAwt/
HRD<33, had a worse PFS result (PFS hazard ratio 0.71, 95% CI
0.34–1.46, n= 41; 21 olaparib, 20 placebo) than the HRD-negative
group (BRCAwt, HRD score <42) or the BRCA-mutated and/or
HRD ≥33 group (PFS hazard ratio 0.25, 95% CI 0.16–0.38, n= 185,
97 olaparib, 88 placebo).
Markers associated with long-term treatment
In Study 19 there were 16 patients treated for 6 years or longer,
of whom one was on placebo and had a germline mutation in
BRCA1. Of the 15 patients on olaparib for more than 6 years, 8
were originally reported as having BRCA mutations.7 One further
patient was found to have somatic mutations in both BRCA1 and
BRCA2 on Myriad blood and tumour testing (no Foundation
Medicine tumour testing data were available); hence, 9/15
patients are known to have a BRCA mutation (5 with BRCA2,
3 with BRCA1 and 1 with both) in their tumour or blood sample,
with 3/9 being a somatic mutation. This enrichment for BRCA2
mutation and presence of somatic cases in long-term respon-
ders has been noted previously.20 One of the remaining six
patients was not evaluable for tBRCA status at either Myriad or
Foundation Medicine, hence 5/15 patients treated with olaparib
for more than 6 years had no detectable BRCA mutation. Three
out of five patients had Myriad HRD scores available (2x HRD
positive and 1x HRD negative) and 5/5 had HRRm status
available (1x HRRm, 2x HRR uncertain, 2x HRRwt). Of the two
HRRwt tumours, one was Myriad HRD negative (Myriad HRD
score 15) and the other was Myriad HRD status unknown.
Therefore, patients without BRCA-mutated tumours and whose
tumours tested negative for additional candidate biomarkers
(HRRwt or BRCAwt HRD negative) were found among the
patients who remained on olaparib for over 6 years.
Immunohistochemistry for BRCA1
Staining was performed on duplicate cores on the tissue
microarrays generated from the 145 patients submitting a tumour
block (Supplementary Table 4). A trend for less staining in BRCA1-
mutated cases was observed (Supplementary Table 5). However,
there was no indication of a prognostic or predictive effect on PFS
of BRCA1 protein levels determined by immunohistochemical
staining using Cox regression analysis.
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DISCUSSION
Elegant preclinical experiments led to the concept of synthetic
lethality, which suggested that tumours without functional
BRCA1 or BRCA2 protein would be more susceptible to PARP
inhibitors compared with non-tumour tissues in the same
patients.21 In this model, PARP inhibition leads to an accumula-
tion of unrepaired single-strand breaks in DNA, which are
converted to double-strand breaks when the tumour cell
attempts DNA replication in the S-phase. The resulting double-
strand breaks are then repaired in non-tumour cells that are
proficient in HRR but accumulate and lead to mitotic cata-
strophe in tumour cells that are HRR deficient. BRCA1 and BRCA2
play important roles in homologous recombination and, in
germline carriers of mutations, loss of the remaining un-mutated
copy of the gene and concomitant loss of function is thought to
occur early in the development of ovarian and breast cancer.22
Hence, early clinical studies with the PARP inhibitor olaparib
focused on tumours in germline-mutated BRCA carriers and
confirmed activity in patients with breast and ovarian can-
cer.23,24 Preclinically, deficiencies in other proteins involved in
homologous recombination conferred sensitivity to PARP
inhibition, albeit with a lesser impact than BRCA deficiency5
and high-grade SOC was initially thought to represent a
particularly promising tumour type for PARP inhibitor therapy
because, in addition to a high frequency of BRCA mutations, it is
characterised by large-scale genomic instability and repeated,
durable platinum sensitivity (considered likely to be hallmarks of
HRR deficiency). In support of this theory, a non-randomised
study of olaparib monotherapy in ovarian cancer subsequently
found response rates of 41% and 24% in the germline BRCA-
mutated and non-mutated carrier patient populations, respec-
tively.25 Therefore, it was expected that the non-BRCA-mutated
carrier high-grade SOC patient population included a significant
number of patients whose tumours could be susceptible to
PARP inhibition and Study 19 was a placebo-controlled study in
the maintenance setting designed to test this hypothesis.7 Study
19 was a positive study overall and in a preplanned subgroup
analysis the magnitude of PFS effect was greater in patients who
had a BRCA mutation than those without.7 Tumour testing in
Study 19 successfully identified the vast majority of germline
BRCA-mutated cases and identified a further subset of patients
with somatic or tumour only mutations.7 Subsequent explora-
tory analyses suggested that tumours with somatic BRCA
mutations phenocopy those from germline carriers, both in
terms of tumour genetics and in clinical benefit on olaparib10
and a clinical trial is under way to confirm this observation.26
Hence, BRCA mutation testing of tumour samples is the clearest
indicator of tumour responsiveness to olaparib treatment in
current clinical practice. Importantly, the data presented here
confirm a very high level of consistency in research testing for
tumour BRCA mutations in two independent laboratories and
therefore confirms our previous observation that tumour testing
accurately detects germline mutations. The number of muta-
tions not captured by the Foundation Medicine assay was
relatively small (n= 3, all indels). Nonetheless, it is important
that all tumour testing laboratories further develop their
methodologies to accurately detect rare variants to allow
tumour testing to detect all clinically relevant mutations.
We have shown that Study 19 contained a readily identifiable,
biologically coherent subpopulation of patients with inherited or
acquired mutations in BRCA1 or BRCA2 who gain a PFS benefit
from olaparib treatment. It is important that we determine
whether there is a molecularly identifiable subgroup of patients
with BRCA wild-type tumours that is differentiated from patients
solely selected on available clinical parameters of platinum
sensitivity and high-grade serous histology used in Study 19.
Furthermore, if such a subgroup exists it will be important to
determine whether the differential in benefit is clinically mean-
ingful. Several candidate molecular measures have been sug-
gested to fulfil this role including a continuous measure of
genomic instability or HRR deficiency ‘scar’, BRCA1 methylation
and loss-of-function mutations in other homologous recombina-
tion pathway genes. The supporting data behind the candidate
biomarkers investigated are summarised in Table 2.
Here, we report that the ovarian BRCA wild-type patient
population may include a majority of patients whose tumours
lack DNA repair gene loss-of-function mutations and who gain
less benefit from PARP olaparib treatment than patients
with candidate loss-of-function mutations in genes involved in
HRR.
First, we attempted to identify patients with loss-of-function
mutations in candidate HRR genes in their tumours. Clearly this
approach is limited by the genes sequenced by the Foundation
Medicine panel and by the relative absence of relevant preclinical
and clinical data. We therefore chose a pragmatic approach to
include all genes with a DNA repair pathway role and some
supportive preclinical data. Subsequently, we defined a higher
confidence patient population by differentiating between candi-
date genes in which the primary role is related to mismatch repair
or where, despite a purported role in double-strand DNA repair,
either the genetic mechanism is distinct and/or the phenotypic
impact on platinum sensitivity and prognosis in ovarian cancer is
Table 2. Summary of data to support investigation of candidate biomarkers
Candidate biomarker Summary of evidence base References
BRCA1 methylation Multiple independent reports in ovarian cancer suggesting (i) mutual exclusivity with BRCA1 mutations (ii)
coincidence with BRCA1 loss of heterozygosity. However, no reported BRCAm-like link to good prognosis and
platinum sensitivity
37,38
BRCA1 protein Low protein levels linked to increased duration of survival in platinum-treated ovarian cancer. However, some
difficulties in reproducing data
39–41
HRR gene mutations Preclinically linked to PARP inhibitor sensitivity. Mechanistically analogous to BRCAm and linked to prolonged
survival and platinum sensitivity in ovarian cancer. However, difficult to gauge impact of individual genes due to
low prevalence and some evidence of non-mutual exclusivity
5,8
HRD score Sensitive for BRCAm and BRCA1 methylation, relatively conserved between primary and metastatic lesions.
Prognostic for and linked to higher platinum response rate. Evidence from ovarian cancer trials: shorter
progression-free survival in patients with HRD-positive tumours without BRCA mutations vs those with BRCA
mutations. Longer progression-free survival in patients with HRD-positive vs HRD-negative tumours; however,
may serve as a genomic scar that is irreversible and unreflective of current tumour phenotype and, unlike BRCAm,
was not predictive for platinum vs taxane in the TNT trial in breast cancer
11,12,17,42,43
BRCAm BRCA mutation, HRD homologous recombination deficiency, HRR homologous recombination repair
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directionally opposed to that of BRCA mutations (i.e., EMSY
amplification and PTEN loss).8
We identified 37 patients with mutations in any gene involved
in DNA repair, of these patients 21 had mutations in the (relatively)
higher confidence gene set. Genes involved in more than one
patient were BRIP1 (n= 5), CDK12 (n= 3), RAD54L (n= 2) and
RAD51B (n= 2). BRIP1 (BRCA1 interacting protein C-terminal
helicase 1) is a protein that works with BRCA1 to repair damaged
DNA and the inheritance of two mutated copies of BRIP1 causes
Fanconi anaemia. Women who inherit one mutated copy of BRIP1
are likely to have an increased risk of ovarian cancer; however, the
implication of this for breast cancer risk is inconclusive.27–29
CDK12 is the least validated gene included in our HRR gene list.
It is biallelically inactivated in ovarian cancer; hypothesis-directed
experiments have found that mutations or depletion are
associated with sensitivity to radiation, platinum or PARP inhibitor
treatment and it was also highlighted as a candidate gene in a
hypothesis-free synthetic lethal screen approach.30,31 However,
mechanistically it has been proposed to have an indirect effect on
DNA repair via transcriptional regulation32 and it was recently
suggested to be associated with a different pattern of genome
instability than that seen in patients with BRCA mutations or
BRCA1 methylation.33
The number of patients with mutations in any HRR gene (other
than BRCA1 or BRCA2) in Study 19 is too small to derive definitive
conclusions. Furthermore, because of the low prevalence of
mutations in any one gene a similarly sized trial could easily result
in a different profile of mutated genes. However, it was possible to
define a subpopulation of 58 patients without a candidate loss-of-
function mutation in any measured relevant HRR gene. While it is
acknowledged that mutations or alterations in other unmeasured
genes may not have been detected in these 58 patients, it is
notable that for all efficacy measures there was marked
attenuation of the treatment benefit from olaparib. Our data are
consistent with those of another study,8 suggesting that tumours
with mutations in HRR genes may be associated with increased
platinum sensitivity and prolonged survival.
While these data are encouraging, significant challenges
remain, due to the differing biological role of each gene and
the low prevalence of mutations in any one gene. Hence,
determining utility for clinical decision-making suffers from the
analogous issues facing genetic teams with low prevalence/
penetrance inherited gene mutations, although the risk–benefit
profile for the treatment decisions in a cancer patient may be
arguably different to that for prophylactic surgery. Further data are
needed to confirm this observation and there is a need for the
clinical, research and regulatory community to understand what
evidence base can be required for individual or ‘buckets’ of low
prevalence genes with high biological plausibility. Exploratory
analyses of the recently reported ARIEL2, ARIEL3 and NOVA trials
could significantly add to the present evidence base available.11–13
The ability to avoid these issues for causal genetic changes
and use an HRD score or genomic read-out of the effects of HRD,
regardless of causal mechanism, is inherently attractive in
theory. In Study 19 there were only 36 patients with BRCA
wild-type tumours with a high Myriad HRD score. In agreement
with data presented from a preliminary analysis of the NOVA
trial we note that HRR-mutated patients tend to have higher
Myriad HRD scores in Study 19 but that BRIP mutations appear
to have a weak correlation such that, in both Study 19 and the
preliminary NOVA data, only half of BRIP-mutated tumours were
HRD score positive. In Study 19 only half of all the HRD score
evaluable HRR-mutated patients were HRD positive (scores ≥42),
whereas 14 of the 15 patients with BRCA1 methylation who were
evaluable for HRD score were HRD positive. BRCA1-methylated
cases accounted for at least 39% of the BRCA wild-type HRD-
positive population in Study 19. An exploratory analysis of the
36 BRCA wild-type Myriad HRD-positive cases suggested that
these patients were only marginally more likely to benefit from
olaparib than selection based on study entrance criteria
(response to platinum and high-grade serous histology); it may
be that this is largely because of an inability of BRCA1
methylation to phenocopy BRCA1 mutation in terms of olaparib
sensitivity/ease of reversibility as has also been reported for
platinum sensitivity.8 The BRCA wild-type HRD scores ≥42
analysis reported here is an exploratory analysis of a small
number of patients (n= 36) and aligns with the recently
reported data for the NOVA and ARIEL3 trials which used the
Myriad HRD (42) score and Foundation Medicine LOH score,
respectively.12,13 In further exploratory analysis of Study 19, we
show that relaxing the HRD threshold to a value of 33
differentiates a potential population receiving enhanced benefit
compared to patients below the new threshold (hazard ratio
0.71 in HRD score <33 vs hazard ratio= 0.25 in HRD score ≥33).
Particularly in a setting where the majority of patients appear to
derive some level of benefit from PARP inhibitors, considering a
biomarker that aims to exclude those patients least likely to
benefit, rather than identifying those that are most likely to
benefit, might be an attractive strategy. Compared to the HRD
threshold of 42, this modified HRD scar approach, using a
threshold <33, may have the potential to better identify a
patient population that would derive least benefit from PARP
inhibitors, but requires further study.
Importantly, although we observed an enrichment for BRCA2
mutations in the long-term responders, neither an HRRm or HRD
approach was able to exclude patients who remained on
treatment for 6 years or more. It is likely that additional
mechanisms, such as those relating to the immune system, are
important in determining which patients may receive long-term
benefit from olaparib and potentially also from chemotherapy.34,35
CONCLUSIONS
In summary, the analyses reported here demonstrate that next-
generation sequence-based tumour testing for BRCA mutations in
clinically available FFPE samples can be highly reproducible and
may identify a subpopulation of patients with the greatest PFS
benefit from olaparib. A measure of HRD or genomic instability
(Myriad MyChoice HRD) identified most patients with BRCA
mutations and nearly all patients with BRCA1 methylation;
however, only ~50% of a small number of patients with mutations
in other candidate HRR genes were identified as HRR deficient. In
underpowered exploratory analyses (i) patients with BRCA wild-
type HRD-positive tumours did not achieve as high a treatment
benefit from olaparib as patients with BRCA-mutated tumours and
(ii) patients with tumours without mutations in candidate HRR
genes, which comprised the majority of the BRCA wild-type
subpopulation, received the least benefit from olaparib treatment,
an observation which may be particularly important in the
maintenance setting in the absence of any acute indicator of
tumour response to olaparib treatment.
Further clinical studies examining all candidate tumour DNA-
based measures of cause and effect deficiencies in HRR pathways
are required to confirm that these additional measurements can
provide clinically relevant information and treatment benefits for
patients with BRCA wild-type high-grade SOCs.
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